RFK, the FDA, and the Future of Peptides: What's Actually Changing

Recent statements from U.S. Health and Human Services Secretary Robert F. Kennedy Jr. suggest the FDA could loosen restrictions on a group of peptides that were effectively banned just a few years ago.

So what's actually happening?

What Changed

In 2023, the FDA placed a group of peptides into what's known as "Category 2" — a classification that prevents compounding pharmacies from producing them due to safety concerns.

This included compounds like:

• BPC-157
• TB-500
• KPV
• GHK-Cu
• CJC-1295
• Ipamorelin

The reasoning was simple:

• Limited human data
• Concerns around purity and manufacturing
• Unknown long-term safety

That move effectively removed legal access through traditional medical channels.

RFK's Position

RFK Jr. has publicly pushed back on that decision.

He has suggested that roughly 14 of those peptides could be moved back into a category that allows compounding pharmacies to produce them again under physician oversight.

The idea isn't full approval. It's controlled access.

In his view, regulated supply is safer than forcing demand into unregulated markets.

What the FDA Is Doing Now

The FDA is currently reviewing whether broader access should be allowed again, with advisory panels expected to evaluate specific peptides and their risks.

This includes compounds commonly discussed for:

• Recovery
• Inflammation
• Metabolic health
• Longevity

At the same time, regulators are still cautious. Many of these peptides:

• Lack large-scale human trials
• Have limited long-term data
• Vary significantly in quality depending on source

Reclassification simply means they can be compounded again under stricter, regulated conditions. That's very different from full approval.

Why This Matters

This could be a turning point.

Right now, demand for peptides is already massive — but much of it exists outside regulated systems. That creates problems:

• Inconsistent quality
• Dosing uncertainty
• Lack of transparency

A shift toward regulated compounding could improve safety standards, increase research interest, and reduce reliance on gray-market sources.

Even critics of the move agree on one thing: the space is growing fast, regardless of regulation.

The Bigger Trend

Zoom out, and this isn't just about RFK or the FDA. It's about a broader shift.

People are moving toward:

• Precision health
• Targeted signaling (not blanket treatments)
• Systems over guesswork

Peptides sit directly in that trend. But the infrastructure around them hasn't caught up. Yet.

Where This Leaves People Right Now

Today, the reality is simple:

• Some peptides are FDA-approved (like GLP-1 drugs)
• Many others are not
• Research is still evolving
• Regulation is actively changing

That makes clarity more important than ever.

So What Should People Actually Do?

Not guess. Not rely on random sources. Not track things in their head.

The entire peptide space is becoming more structured. And the people who benefit most will be the ones who treat it that way.

Built for This Moment

Protocol exists for exactly this reason. Track what you're using, how much you're using, and how it changes over time.